JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version for Ortho-McNeil’s anticonvulsant Topamax® (Topiramate) Tablets, 25 mg, 50 mg, 100 mg and 200 mg. Shipment of this product has commenced.
